ASP Isotopes Inc. Common StockAdvancing stable-isotope facilities with first Silicon-28 and Carbon-14 shipments expected in H2, and Ytterbium-176 production planned later this year.

ASP Isotopes expects several business units to enter commercial production or expand output over the next six months, with CEO Paul Mann highlighting progress in helium, LNG, stable isotopes and radiopharmaceuticals. Renergen has begun Phase 1 helium production in South Africa, with initial customer shipments expected in September and free cash flow targeted by year-end; Phase 2 could significantly expand output, with first production projected for 2030. ASP Isotopes is advancing its stable-isotope facilities, with first Silicon-28 and Carbon-14 shipments expected in the second half of the year and Ytterbium-176 production planned later this year. The company is pursuing growth in semiconductor materials, medical isotopes and radiopharmaceuticals, while targeting a Quantum Leap Energy spinoff by year-end and $300 million in EBITDA by 2031.
ASP Isotopes Inc. Common StockAdvancing stable-isotope facilities with first Silicon-28 and Carbon-14 shipments expected in H2, and Ytterbium-176 production planned later this year.
Renergen has begun Phase 1 helium production in South Africa, with initial customer shipments expected in September and free cash flow targeted by year-end.